Generation of Cisplatin-Resistant Ovarian Cancer Cell Lines Cisplatin Resistance in Ovarian Cancer Cell Lines
Iranian Journal of Pharmaceutical Sciences,
مجلد 12 عدد 1 (2016),
15 January 2016
,
الصفحة 11-20
https://doi.org/10.22037/ijps.v12.40782
الملخص
Ovarian cancer is the most lethal gynecological cancer in which cisplatin-based treatment plays a fundamental role as the first line chemotherapy option. However, development of platinum-resistance is a critical and poorly understood problem in ovarian cancer treatment. Although in vitro generation of platinum-resistant ovarian cancer cell lines is a long established approach to uncover the molecular mechanisms underlying resistance development, the methodology of this resistance induction is poorly explained in publications. The aim of this study was to propose a method for induction of resistance in ovarian cancer cell lines. To reach this aim, A2780 human ovarian cancer cell line was continuously exposed to stepwise increasing concentrations of cisplatin (0.5–2.6μM) over a period of 6 months and three resistant sublines were collected. Cisplatin resistance was examined by clonogenic survival assay and growth curve analysis was carried out in order to evaluate the proliferation characteristics of the established sublines. The A2780 resistant sublines exhibited 5.1 to 11.7 fold resistance to cisplatin, compared to their parental cells, and although growth rate and plateau saturation density significantly decreased by cisplatin resistance enhancement, all three resistant sublines presented a typical growth curve even though they were cultured in the cisplatin containing medium. These results suggest that reliable drug resistant human ovarian cancer cell lines can be successfully established by this method.
- A2780
- A2780-CP
- cell line model
- cisplatin
- ovarian cancer
- resistance induction
كيفية الاقتباس
المراجع
[2] Lloyd KL, Cree LA, Savage RS. Prediction of resistance to chemotherapy in ovarian cancer: a systematic review. BMC Cancer (2015)15:117-149.
[3] Ushijima K. Treatment for recurrent ovarian cancer—at first relapse. Journal of Oncology (2010)2010: Article ID 497429.
[4] Ling KS, Chen GD, Tsai HJ, Lee MS, Wang PH, Liu FS. Mechanisms involved in chemoresistance in ovarian cancer. Taiwanese J Obstet Gynecol (2005) 44(3): 209–217.
[5] Eckstein N. Platinum resistance in breast and ovarian cancer cell lines. Journal of Experimental & Clinical Cancer Research (2011)30: 91-102.
[6] Nicolantonio et al. Cancer cell adaptation to chemotherapy. BMC Cancer (2005)5:78-94.
[7] Wang J, Wu GS. Role of autophagy in cisplatin resistance in ovarian cancer cells. Journal of Biological chemistry (2014)289(24): 17163–17173.
[8] Wilson TR, Longley DB, Johnston PG. Chemoresistance in solid tumours. Annals of Oncology (2006)17(10): 315–324.
[9] Zhang X, Yashiro M, Qiu H, Nishii T, Mastsuzaki T, Hirakawa K. Establishment and characterization of multidrug-resistant gastric cancer cell lines. Anticancer Research (2010) 30: 915-922.
[10] Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J Pathol (2005)205: 275–292.
[11] Huang et al. Induction of acquired drug resistance in endothelial cells and its involvement in anticancer therapy. Journal of Hematology & Oncology (2013)6: 49-60.
[12] Garajová I, Large TYL, Frampton AF, Rolfo C, Voortman J, Giovannetti E. Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer. BioMed Research International (2014)2014: Article ID 678401.
[13] Allen KE, Weiss GJ. Resistance may not be futile: microRNA biomarkers for chemoresistance and potential therapeutics. Mol Cancer Ther (2010)9(12): 3126-3136.
[14] Oh JH, Deasy JO. A literature mining-based approach for identification of cellular pathways associated with chemoresistance in cancer. Brief Bioinform (2015) doi: 10.1093/bib/bbv053.
[15] Lippert TH, Ruoff HJ, Volm M. Current status of methods to assess cancer drug resistance. Int. J. Med. Sci. (2011)8(3): 245-253.
[16] Gillet JP, Varma S, Gottesman MM. The clinical relevance of cancer cell lines. J Natl Cancer Inst (2013)105: 452–458.
[17] Gillet et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. PNAS (2011)108(46): 18708–18713.
[18] Britten RA, Kuny S, Perdue S. Modification of non-conservative double-strand break (DSB) rejoining activity after the induction of cisplatin resistance in human tumour cells. British Journal of Cancer (1999)79(5/6): 843–849.
[19] McDermott et al. In vitro development of chemotherapy and targeted therapy drug-resistant cancer cell lines: a practical guide with case studies. Frontiers in Oncolog (2014) 4 : doi: 10.3389.
[20] Behrens BC, Characterization of a cis-Diamrninedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Research (1987)47: 414-418.
[21] PU QQ, Benzwoda WR. Induction of alkylator (melphalan) resistance in HL60 cells is accompanied by increased levels of topoisomerase II expression and function. Molecular Pharmacology (1999)56: 147–153.
[22] Barr et al. Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem- like signature. Plosone (2013)8(1): e54193.
[23] Perego et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Research (1996)56: 556-562.
[24] El-akawil Z. Abu-hadid M, Perez R, Glavy J, Zdanowicz J, Creaven PJ, Pendyala L. Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells. Cancer Letters (1996)105: 5-14.
[25] Nikounezhad N, Shirazi FH, Kamalinejad M. Relative cytotoxicity of fractionated extract of arial parts of Mentha Pulegium on three cancer cell lines. Am. J. PharmTech Res. (2014)4(6): 215-223.
[26] Goto T, Takano M, Hirata J , Tsuda H. The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers. British Journal of Cancer (2008) 98: 1068 – 1075.
[27] Troger V, Fischel JL, Formento P, Gioanni J, Milano G. Effects of prolonged exposure to cisplatin on cytotoxicity and intracellular drug concentration. Eur J Cancer (1992)28(1):82-6.
[28] Rolland LR, Murrer BA, Abel G, Giandomenico CM, Mistry P, Harrap KR. Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines. Cancer Research (1992)52: 822-828.
[29] Wosikowski K, Silverman JA, Bishop P, Mendelsohn J, Bates SE. Reduced growth rate accompanied by aberrant epidermal growth factor signaling in drug resistant human breast cancer cells. Biochimica et Biophysica Acta (2000)1497: 215-226.
[30] Zhou Y, Ling XL, Li SW, Li XQ, Yan B. Establishment of a human hepatoma multidrug resistant cell line in vitro. World J Gastroenterol (2010)16(18): 2291-2297.
[31] Létourneau et al. Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer. BMC Cancer (2012)12: 379-395.
[32] Twentyman PR, Fox NE,Wright KA, Bleehen NM. Derivation and preliminary characterisation of adriamycin resistant lines of human lung cancer cells. Br. J. Cancer (1986)53: 529-537.
[33] Mattern J. Cellular drug resistance in lung cancer. Cancer Therapy (2004)2: 403-414.
[34] Yan XD, Li M, Yuan Y, Mao N, Pan LY. Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations. Oncology Reports (2007)17: 1163-1169.
[35] Frei et al. Alkylating agent resistance: In vitro studies with human cell lines. Proc. Nati. Acad. Sci. USA (1985)2(82): 2158-2162.
[36] Yang LY, Trujillo JM. Biological characterization of multidrug-resistant human colon carcinoma sublines induced/selected by two Methods. Cancer Research (1990) 50: 3218-3225.
[37] Kuppen PJK, Schuitemaker H, LJV, Bruijn EAD, Schrier PI. Cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines. Cancer Research (1988) 48: 3355-3359.
[38] Borst P. Cancer drug pan-resistance: pumps, cancer stem cells, quiescence, epithelial to mesenchymal transition, blocked cell death pathways, persisters or what? Open Biol (2012)2: 120066.
- الملخص المشاهدات: 81 الأوقات
- IJPS_Volume 12_Issue 1_Pages 11-20 (English) التنزيلات: 16 الأوقات